Analyst Ratings For AnaptysBio Inc (NASDAQ:ANAB)
Today, AnaptysBio Inc (NASDAQ:ANAB) stock was downgraded by Stifel Nicolaus from Buy to Hold with a price target of $74.00.
There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AnaptysBio Inc (NASDAQ:ANAB) is Buy with a consensus target price of $117.2727 per share, a potential 97.00% upside.
Some recent analyst ratings include
- 6/21/2019-AnaptysBio Inc (NASDAQ:ANAB) gets downgraded to Hold by Stifel Nicolaus with a price target of $74.00
- 6/21/2019-AnaptysBio Inc (NASDAQ:ANAB) gets downgraded to Neutral by Credit Suisse Group with a price target of $79.00
- 3/1/2019-AnaptysBio Inc (NASDAQ:ANAB) had its Outperform rating reiterated by Wedbush
- 2/22/2019-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Buy rating and $135.00 price target
- 12/20/2018-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Buy ➝ Buy rating and $126.00 price target
- On 6/10/2019 Hamza Suria, CEO, sold 22,428 with an average share price of $73.76 per share and the total transaction amounting to $1,654,289.28.
- On 6/4/2019 Marco Londei, Insider, sold 10,060 with an average share price of $73.06 per share and the total transaction amounting to $734,983.60.
- On 1/15/2019 Marco Londei, Insider, sold 19,075 with an average share price of $69.88 per share and the total transaction amounting to $1,332,961.00.
- On 1/14/2019 Hamza Suria, CEO, sold 40,000 with an average share price of $70.79 per share and the total transaction amounting to $2,831,600.00.
- On 12/17/2018 Marco Londei, Insider, sold 30,048 with an average share price of $66.76 per share and the total transaction amounting to $2,006,004.48.
- On 12/14/2018 Hamza Suria, CEO, sold 41,728 with an average share price of $69.36 per share and the total transaction amounting to $2,894,254.08.
- On 12/12/2018 Hamza Suria, CEO, sold 65,585 with an average share price of $71.47 per share and the total transaction amounting to $4,687,359.95.
About AnaptysBio Inc (NASDAQ:ANAB)
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. Read More…
Recent Trading Activity for AnaptysBio Inc (NASDAQ:ANAB)
Shares of AnaptysBio Inc closed the previous trading session at 59.68 −7.34 10.95% with 1488454 shares trading hands.
